Hormone Receptor Positive Tumor Recruiting Phase 2 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0075370 (Hormone Receptor Positive Tumor)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03409198Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast CancerTreatment